Background {#Sec1}
==========

Pain management is a crucial component in postoperative care of the surgical patient. The combination of non-opioid and opioid analgesics, known as multimodal analgesia, is a cornerstone in the treatment of postoperative pain. Gabapentin has recently become a part of a wide array of postoperative multimodal analgesic regimens \[[@CR1]--[@CR3]\].

It has been argued that postoperative pain treatment should be "procedure-specific", that is, adapted to the particular surgical procedure, since different analgesics may have specific effects dependent on the nature of the surgery \[[@CR4], [@CR5]\].

Gabapentin has been used in postoperative pain management since 2002. It is an anti-epileptic drug presumed to affect nociceptive processing through α2δ-subunits of voltage gated calcium channels, thereby causing decrease in excitatory neurotransmitters, e.g. glutamate, substance P and calcitonin gene-related peptide (CGRP) \[[@CR6], [@CR7]\]. The anti-hyperalgesic properties have been investigated in several experimental and clinical trials \[[@CR8]--[@CR11]\].

In a recent systematic review we pooled data from all clinical trials and different surgical interventions with gabapentin \[[@CR12], [@CR13]\]. The conclusion from this review was, that firm evidence for use of gabapentin is lacking, as clinically relevant beneficial effects of gabapentin may be absent and harm is imminent, especially when added to multimodal analgesic regimens \[[@CR12]\]. In the present preplanned subgroup analyses and post hoc analyses, we aimed to compare the procedure-specific effects of peri-operative gabapentin on postoperative opioid consumption, pain intensity, and adverse- and serious adverse events in six different surgical procedures. It was our hypothesis that the reduction in 24-h morphine consumption and incidence of SAE's would differ between surgical procedures.

Methods {#Sec2}
=======

These are preplanned subgroup analyses and post hoc analyses from a systematic review following the methodology recommended by the Cochrane Collaboration. The protocol was published in the International Prospective Register of Systematic Reviews (PROSPERO) ([www.crd.york.ac.uk/PROSPERO](http://www.crd.york.ac.uk/PROSPERO/)) registration no. CRD42013006538 \[[@CR13]\].

Search strategy {#Sec3}
---------------

The search was planned by a trial search coordinator using the Cochrane Library's CENTRAL, PubMed, EMBASE, and Science Citation Index Expanded databases. Previous reviews, reference lists and Google Scholar were hand-searched for eligible trials. Www.[clinicaltrials.gov](https://clinicaltrials.gov); [www.controlled-trials.com](http://www.controlled-trials.com/); [www.centerwatch.com](http://www.centerwatch.com); [www.eudraCT.com](https://eudract.ema.europa.eu/), and at the homepage of the US Food and Drug Administration (FDA) were searched for unpublished trials. Non-English articles were translated to English. The electronic search (Additional file [1](#MOESM1){ref-type="media"}: Appendix 1 - search strategies) was last updated April 12th, 2016.

Data extraction {#Sec4}
---------------

After removal of duplicates, titles and abstracts were screened by two authors (MLF, AG). MLF and one other independent author (AG, MSH, PLP, LN) assessed full texts, extracted data and assessed bias. The following characteristics were extracted from the trials using a data extraction form: Year of publication, number of participants, type of surgery, follow-up period and dose regimen, consumption of opioid, and non-opioid medication, pain intensity, and any adverse events described in the trials, including serious adverse events (SAEs).

The corresponding author was contacted whenever data were insufficiently reported, and contact was repeated after 14 days. In case of no response, the involved bias domains were classified as unclear.

Risk of bias assessment {#Sec5}
-----------------------

Risk of bias was assessed using The Cochrane Handbook guidelines. All trials were classified as low, unclear or high risk of bias using the following domains: Random sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting and other bias, including funding and confirmatory bias.

Disagreements between authors on study selection, data extraction or bias assessment were solved by OM, JBD or JW.

We decided a priori to report and conclude based primarily on results from trials classified as low risk of bias.

Small trial size {#Sec6}
----------------

All trials were evaluated in this post hoc analysis and allocated to the corresponding group according to the numbers of participants included in the analyses. Small trials were defined as trials with less than 50 patients included in each group. Trials were allocated to the remaining two groups if they included either more than 50 patients, or more than 200 patients \[[@CR12]\].

Analyses {#Sec7}
--------

The present subgroup analyses of surgical procedures were predefined in the protocol investigating the effect of different surgical procedures: Cholecystectomy, hysterectomy, mastectomy, orthopedic arthroplasty surgery, spinal and thoracic surgery on the primary and secondary outcomes. Analyses of thoracic surgery and orthopedic arthroplasty surgery have been added post hoc \[[@CR13]\]. The surgical procedures were chosen to represent a wide range of surgical interventions and patient populations. Cholecystectomy is a minor procedure, often performed as day-case surgery, whereas thoracic surgery is a major procedure, which may be associated with intensive care in the immediate postoperative period. Mastectomy and hysterectomy are procedures with moderate to severe pain postoperatively. Orthopedic arthroplasty and spinal surgery often represents patients with chronic pain preoperatively. We chose to add trials investigating thoracic surgery and orthopedic arthroplasty surgery post hoc, in order to broaden the range of surgical interventions.

The planning and interpretation of the subgroup analyses followed the direction of the Cochrane Handbook \[[@CR14]\].

Outcomes {#Sec8}
--------

The primary outcomes were difference in 24-h postoperative opioid sparing effects, and reported serious adverse events (SAE) between surgical procedures. SAE's were defined according to the International Conference of Harmonization -- Good Clinical Practice (ICH-GCP) definitions: Medical events being either life threatening, resulting in death, disability or significant loss of function, or causing hospital admission or prolonged hospitalization \[[@CR15]\].

Secondary outcomes were differences in early (6-h) and late (24-h) pain postoperatively, both at rest and during mobilization, and all other adverse events, between surgical procedures.

All opioids were converted to intravenous morphine based upon equivalency as presented in Additional file [1](#MOESM1){ref-type="media"}: Appendix 2. Various scales were used to report pain intensity in the trials. All pain intensity scales reporting pain levels between 0 and 10 were converted to the Visual Analogue Scale (VAS) 0 to 100 mm.

Statistical analysis {#Sec9}
--------------------

Review Manager (RevMan) \[Computer program\], Version 5.1.6, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014, and Trial Sequential Analysis (TSA) software (version 0.9.5.5 Beta), Copenhagen Trial Unit, Denmark, was used for statistical analyses as predefined in the protocol.

In trials with more than one active treatment arm, including trials testing doses delivered pre- and immediate postoperatively, means and standard deviations were combined for the intervention groups.

Mean and standard deviations were estimated from median and range values according to the method described by Hozo et al. \[[@CR16]\] Standard deviations were calculated by dividing the difference in interquartile ranges with 1.35 \[[@CR14]\].

Longer ordinal scales were analyzed as continuous data. For dichotomous data, RR with a 95% confidence interval was calculated.

We examined the heterogeneity between trials using chi-squared test. The heterogeneity was measured by I^2^, which quantifies inconsistencies. If the I^2^ was greater than zero the results were calculated using both a fixed effect model (FEM) and random effect model (REM) and the most conservative estimation was used \[[@CR14], [@CR17]\]. In the case of very few and rare events, Peto's odd ratio was used to provide the best coverage of confidence intervals \[[@CR18], [@CR19]\].

Estimates were pooled in meta-analyses whenever more than one trial was included for the outcome. Tests for subgroup differences were carried out for all surgical procedures on all outcomes whenever a meta-analysis was possible. Using RevMan, the method to test for subgroup differences was implemented for all types of meta-analyses \[[@CR14]\]. Our test for subgroup differences was performed on each of the subgroups testing them for subgroup differences against the compiled, remaining subgroups using the chi-squared test.

We used Trial Sequential Analysis (TSA) in post hoc analyses to adjust the confidence intervals for sparse data and repetitive testing. Minimal clinical relevant differences were defined as in our main review \[[@CR12]\]. In the event that the accrued information size was less than 5% of the required information size, no TSA was reported, as the TSA program is unable to calculate trial sequential monitoring boundaries in this situation.

Results {#Sec10}
=======

The search strategies revealed 19,137 titles. Duplicates were removed and 16,303 titles were sorted according to inclusion- and exclusion criteria. One-hundred-thirty-five randomized controlled trials and observational studies were included in the original systematic review. After excluding 61 trials investigating other surgical procedures, a total of 74 randomized controlled trials with 5645 patients were included in the present analyses (Fig. [1](#Fig1){ref-type="fig"}: PRISMA flowchart) \[[@CR20]--[@CR94]\].Fig. 1PRISMA flowchart

Characteristics of included trials {#Sec11}
----------------------------------

Trial characteristics are presented in Table [1](#Tab1){ref-type="table"}. Eight trials were classified as overall low risk of bias, \[[@CR39], [@CR43], [@CR46], [@CR56], [@CR59], [@CR72], [@CR73], [@CR85]\] 18 trials were overall unclear risk of bias \[[@CR21], [@CR23], [@CR24], [@CR26], [@CR28], [@CR29], [@CR31], [@CR36], [@CR38], [@CR42], [@CR52], [@CR54], [@CR55], [@CR61], [@CR65], [@CR66], [@CR68], [@CR69], [@CR80]\] and 48 trials were classified as high risk of bias, \[[@CR20], [@CR22], [@CR25], [@CR27], [@CR30], [@CR32]--[@CR35], [@CR37], [@CR40], [@CR41], [@CR44], [@CR45], [@CR47]--[@CR51], [@CR53], [@CR57], [@CR58], [@CR60], [@CR62]--[@CR64], [@CR67], [@CR70], [@CR71], [@CR74]--[@CR79], [@CR81]--[@CR84], [@CR86]--[@CR94]\] (Fig. [2](#Fig2){ref-type="fig"}: Bias assessment). Allocation concealment, selective outcome reporting and "other bias" were the domains with most unclear or high risk of bias evaluations (Fig. [3](#Fig3){ref-type="fig"}: Risk of bias graph).Table 1Trial characteristicsReference *(Author and year)*Surgical procedureN *Gabapentin/Control*InterventionPostoperative analgesiaAnesthetic techniqueBias assessment*Dose (mg)* *(mg/day* ^a^ *)Single/Continuous*Cholecystectomy trials Bashir 2009 \[[@CR24]\]Laparoscopic cholecystectomy50/50600 mgSingleNot describedGAUnclear Bekawi 2014 \[[@CR26]\]Laparoscopic cholecystectomy30/301200 mg\
(400 mg)ContinuousNSAID\
Pethidine\
TramadolGAUnclear Bhandari 2014 \[[@CR27]\]Laparoscopic cholecystectomy20/20600 mg\
(600 mg)ContinuousNSAIDGAHigh Hosseini 2015 \[[@CR48]\]Laparoscopic cholecystectomy22/22600 mgSingleMorphineGAHigh Khademi 2009 \[[@CR51]\]Open cholecystectomy44/43600 mgSinglePethidineGAHigh Mishra 2016 \[[@CR63]\]Laparoscopic cholecystectomy30/30900 mgSingleTramadolGAHigh Neogi 2012 \[[@CR64]\]Laparoscopic cholecystectomy30/30900 mgSingleTramadolGAHigh Panday 2004b \[[@CR68]\]Laparoscopic cholecystectomy153/153300 mgSingleFentanylGAUnclear Panday 2006 \[[@CR70]\]Laparoscopic cholecystectomy125/125600 mgSingleFentanylGAHigh Pathak 2013 \[[@CR71]\]Open cholecystectomy40/401200 mgSinglePethidineGAHigh Saeed 2013 \[[@CR79]\]Laparoscopic cholecystectomy50/50600 mgSinglePethidine\
NSAIDGAHigh Semira 2013 \[[@CR81]\]Laparoscopic cholecystectomy30/30600 mgSingleNot describedGAHigh Sharma 2015 \[[@CR83]\]Laparoscopic cholecystectomy20/20600 mg\
(600 mg)ContinuousNSAIDGAHigh Srivastava 2009 \[[@CR85]\]Open cholecystectomy60/60600 mgSingleTramadolGALow Syal 2010 \[[@CR86]\]Open cholecystectomy30/301200 mgSingleTramadolGAHigh Takmaz 2009 \[[@CR87]\]Open cholecystectomy30/15900/1200 mgSingleTramadol\
MeripedineGAHighHysterectomy trials Ajori 2011 \[[@CR20]\]Abdominal hysterectomy69/69600 mgSingleMeripedineGAHigh Badawy 2014 \[[@CR23]\]Hysterectomy20/20800 mgSingleMeripedine AcetaminophenGAUnclear Behdad 2012 \[[@CR25]\]Hysterectomy30/31100 mg\
(300 mg/d)ContinuousAn opioidGAHigh Dierking 2003 \[[@CR33]\]Abdominal hysterectomy (salphinooophrectomy)40/401200 mg\
(1800 mg/d)ContinuousMorphineGAHigh Durmus 2006 \[[@CR36]\]Hysterectomy25/251200 mgSingleMorphineGAUnclear Fassoulaki 2005 \[[@CR39]\]Abdominal hysterectomy29/30400 mg\
(1600 mg/d)ContinuousMorphine\
Paracetamol\
CodeineGALow Fassoulaki 2006 \[[@CR40]\]Abdominal hysterectomy30/30400 mg\
(1600 mg/d)ContinuousMorphine\
Paracetamol\
Codeine\
Local anestheticGAHigh Frouzanfard 2013 \[[@CR41]\]Abdominal hysterectomy25/251200 mgSingleMorphine\
NSAIDGAHigh Ghafari 2009 \[[@CR42]\]Abdominal hysterectomy and salphinooophrectomy33/33300 mg\
(300 mg/d)ContinuousMorphineGAUnclear Ghai 2011 \[[@CR43]\]Abdominal hysterectomy30/30900 mgSingleMorphine\
NSAIDGALow Gilron 2004 \[[@CR44]\]Abdominal hysterectomy23/241800 mg\
(1800 mg/d)ContinuousMorphineGAHigh Joseph 2014 \[[@CR50]\]Abdominal hysterectomy25/25600 mgSingleMorphineGAHigh Khan 2013 \[[@CR53]\]Abdominal hysterectomy34/351200 mgSingleNalbuphineGAHigh Ram 2015 \[[@CR75]\]Abdominal hysterectomy30/30900 mgSingleNSAIDSpinal anesthesiaHigh Ray 2015 \[[@CR77]\]Abdominal hysterectomy30/30300 mgSingleNSAIDSpinal anesthesiaHigh Rorarius 2004 \[[@CR78]\]Vaginal hysterectomy45/45600 mgSingleFentanylGAHigh Sekhavet 2009 \[[@CR80]\]Abdominal hysterectomy49/49600 mg\
(300 mg/d)ContinuousMorphine\
NSAIDGAUnclear Sen 2009a \[[@CR82]\]Abdominal hysterectomy and salphinooophrectomy20/201200 mgSingleMorphine\
Acetaminophen\
CodeineGAHigh Turan 2003a \[[@CR88]\]Abdominal hysterectomy and salphinooophrectomy25/251200 mgSingleTramadolGAHigh Turan 2006 \[[@CR90]\]Abdominal hysterectomy and salphinooophrectomy25/251200 mg\
(1200 mg/d)ContinuousAcetaminophen\
CodeineGAHigh Verma 2008 \[[@CR94]\]Abdominal hysterectomy25/25300 mgSingleEpidural analgesiaSpinal-epidural anesthesiaHighMastectomy trials Amr 2009 \[[@CR21]\]Radical or partial mastectomy50/50300 mg\
(300 mg/d)ContinuousMorphine\
Acetaminophen\
CodeineGAUnclear Azemati 2013 \[[@CR22]\]Radical mastectomy or quandrandectomy and axillary node dissection50/50600 mgSinglePethidine\
AcetaminophenGAHigh Bharti 2012 \[[@CR28]\]Total mastectomy with axillary node dissection20/20600 mgSingleMorphine\
NSAIDGAUnclear Butt 2010 \[[@CR29]\]Mastectomy50/501200 mgSingleMorphineGAUnclear Dirks 2002 \[[@CR34]\]Unilateral radical mastectomy with axillary dissection31/341200 mgSingleMorphineGAHigh Doha 2010 \[[@CR35]\]Radical mastectomy30/301200 mgSingleTramadol\
NSAIDGAHigh Fassoulaki 2002 \[[@CR38]\]Radical mastectomy or lobectomy with axillary lymph node dissection25/25400 mg\
(1200 mg/d)ContinuousPropoxyphene\
Acetaminophen\
CodeineGAHigh Gosai 2015 \[[@CR45]\]Radical mastectomy30/30600 mgSingleNSAIDGAHigh Grover 2009 \[[@CR47]\]Total mastectomy with axillary node dissection27/23600 mgSingleMorphineGAHigh Kim 2004 \[[@CR55]\]Mastectomy21/20900 mgSingleFentanylGAUnclear Metry 2008 \[[@CR62]\]Unilateral radical mastectomy and axillary dissection67/341200 mgSingleMorphineGAHighOrthopedic arthroplasty surgery trials Clarke 2009a \[[@CR30]\]Total knee arthroplasty29/7600 mg\
(300/600/900 mg/d)Single/continuousMorphine\
NSAID\
Regional anesthesiaSpinal anesthesia and sedationHigh Clarke 2009b \[[@CR31]\]Total hip arthroplasty76/39600 mgSingle\
(pre/post-operative administration)Morphine\
NSAID\
Acetaminophen\
DexamethasoneSpinal anesthesiaUnclear Clarke 2014 \[[@CR32]\]Total knee arthroplasty95/84600 mgSingleMorphine\
NSAID\
Regional anesthesiaSpinal anesthesia and sedationHigh Lunn 2015 \[[@CR59]\]Total knee arthroplasty186/99900/600 mg (1300/900 mg/d)ContinuousSufentanil\
Oxycodone\
NSAID\
Acetaminophen\
Local infiltration analgesiaSpinal anesthesia and sedationLow Paul 2013 \[[@CR73]\]Total knee arthroplasty52/49600 mg\
(600 mg)ContinuousMorphine\
NSAID\
AcetaminophenSpinal anesthesia and sedationLow Paul 2015 \[[@CR72]\]Total hip arthroplasty48/54600 mg\
(600 mg)ContinuousMorphine\
NSAID\
AcetaminophenSpinal anesthesia and sedationLowSpinal surgery trials Erten 2010 \[[@CR37]\]Laminectomy39/20900/1200 mgSingleTramadol\
Pethidine\
NSAIDGAHigh Khan 2010 \[[@CR52]\]Laminectomy150/25600/900/1200 mg\
(600/900/1200 mg)ContinuousMorphineGAUnclear Khurana 2013 \[[@CR54]\]Discoidectomy30/30300 mg\
(900 mg/d)ContinuousTramadol NSAIDGAUnclear Leung 2006 \[[@CR58]\]Spine surgery9/12900 mg\
(900 mg/d)ContinuousHydromorphineGAUnclear Özgencil 2011 \[[@CR66]\]Laminectomy or discoidectomy30/301800 mg\
(1200 mg/d)ContinuousMorphineGAUnclear Panday 2004a \[[@CR67]\]Discoidectomy80/20300/600/900/1200 mgSingleFentanylGAHigh Panday 2004c \[[@CR69]\]Discoidectomy28/28300 mgSingleFentanylGAUnclear Radhakrishnan 2005 \[[@CR74]\]Laminectomy or Discoidectomy30/30800 mg\
(800 mg/d)ContinuousMorphineGAHigh Turan 2003b \[[@CR89]\]Discoidectomy or spinal fusion25/251200 mgSingleMorphineGAHigh Vahedi 2011 \[[@CR92]\]Laminectomy or\
Discoidectomy36/40300 mgSingleMorphineGAHigh Vasigh 2015 \[[@CR93]\]Laminectomy38/38600 mg\
(900 mg/d)ContinuousMorphineGAHighThoracic surgery trials Grosen 2014 \[[@CR46]\]Thoracotomy for malignancies52/521200 mg\
(increasing dose to 1200 mg/d)ContinuousMorphine\
NSAID\
Acetaminophen\
Epidural analgesiaGALow Hout 2007 \[[@CR49]\]Exploratory thoracotomy, pneumonectomy, lobectomy, segmentectomy, biopsy23/281200 mgSingleHydromorphine\
Epidural analgesiaGAHigh Kinney 2011 \[[@CR56]\]Thoratectomy; Lobectomy; Wedge resection; Segmentectomy; Pneumonectomy; Chest wall resection57/68600 mgSingleFentanyl\
NSAID\
Acetaminophen\
Epidural analgesiaGALow Kosucu 2013 \[[@CR57]\]Posterolateral or lateral thoracotomy29/311200 mgSingleMorphine\
Meriphidine\
NSAIDGAHigh Menda 2010 \[[@CR61]\]Coronary artery bypass graft30/30600 mgSingleMorphine\
AcetaminophenGAUnclear Omran 2005 \[[@CR65]\]Posterolateral thoracotomy for lobectomy25/251200 mg\
(1200 mg/d)ContinuousMorphineGAUnclear Rapchuk 2009 \[[@CR76]\]Cardiac surgery via Sternum27/271200 mg\
(600 mg/d)ContinuousFentanyl\
AcetaminophenGAHigh Soltanzadeh 2011 \[[@CR84]\]Coronary artery bypass graft30/30800 mg\
(400 mg/d)ContinuousMorphineGAHigh Ucak 2011 \[[@CR91]\]Coronary artery bypass graft20/201200 mg\
(1200 mg/d)ContinuousTramadol\
AcetaminophenGAHigh^a^The continuous treatment is defined as more than one administration of gabapentin. The mg/day is the dose of gabapentin per day in the treatments that extends one administration Fig. 2Risk of bias assessment. Risk of bias graph: The 'Other' bias domain is an evaluation of risk of financial bias and confirmatory bias Fig. 3Risk of bias graph. Risk of bias summary

Sixty-six trials were classified as small trials \[[@CR21]--[@CR27], [@CR29]--[@CR31], [@CR33]--[@CR45], [@CR47]--[@CR55], [@CR57], [@CR58], [@CR61]--[@CR64], [@CR66], [@CR67], [@CR69], [@CR71]--[@CR81], [@CR83], [@CR84], [@CR86]--[@CR94]\], five had more than 50 participants in each group \[[@CR20], [@CR32], [@CR46], [@CR56], [@CR85]\], and three included more than 200 patients \[[@CR59], [@CR68], [@CR70]\].

The gabapentin dose in the included trials ranged from 100 mg to 1800 mg, and was mostly administered as a single dose (46 trials). \[[@CR20], [@CR22]--[@CR24], [@CR28]--[@CR32], [@CR34]--[@CR37], [@CR41], [@CR43], [@CR45], [@CR47]--[@CR51], [@CR53], [@CR55]--[@CR57], [@CR61]--[@CR64], [@CR67]--[@CR71], [@CR75], [@CR77]--[@CR79], [@CR81], [@CR82], [@CR85]--[@CR90], [@CR92], [@CR94]\] In 30 trials, gabapentin was administered in combination with a basic, non-opioid/opioid analgesic regimen \[[@CR20], [@CR22], [@CR23], [@CR26], [@CR28], [@CR30]--[@CR32], [@CR37]--[@CR41], [@CR43], [@CR46], [@CR49], [@CR54], [@CR56], [@CR57], [@CR59], [@CR61], [@CR72], [@CR73], [@CR76], [@CR79], [@CR80], [@CR82], [@CR87], [@CR90], [@CR91]\]. In 44 trials, gabapentin was administered together with an opioid as the only analgesic \[[@CR20], [@CR25], [@CR27], [@CR29], [@CR33]--[@CR36], [@CR44], [@CR45], [@CR47], [@CR48], [@CR50]--[@CR53], [@CR55], [@CR58], [@CR62]--[@CR71], [@CR74], [@CR75], [@CR77], [@CR78], [@CR83]--[@CR86], [@CR88], [@CR89], [@CR92]--[@CR94]\]. In five trials, gabapentin was administered in combination with a NSAID \[[@CR27], [@CR45], [@CR75], [@CR77], [@CR83]\],, and in two trials, the postoperative analgesic regimen was not described \[[@CR24], [@CR81]\].

Bias assessments in surgical subgroups {#Sec12}
--------------------------------------

Eight trials were classified as overall low risk of bias. None from the mastectomy subgroup and one trial from the cholecystectomy group was overall low risk of bias \[[@CR85]\]. In the subgroups hysterectomy, \[[@CR39], [@CR43]\] and thoracic surgery \[[@CR46], [@CR56]\] two trials were low risk of bias in each group, and three trials were classified as low risk of bias in the orthopedic arthroplasty subgroup \[[@CR59], [@CR72], [@CR73]\].

Below, we present analyses from trials with low risk of bias. In addition, analyses from all trials are presented in Table [2](#Tab2){ref-type="table"}: Primary outcomes from trials with low risk of bias and all trials estimates, and Table [3](#Tab3){ref-type="table"}: Secondary outcomes from trials with low risk of bias and all trials estimate.Table 2Primary outcomes from trials with low risk of bias and all trials estimatesSurgical procedureCholecystectomyHysterectomyMastectomyOrthopedic arthroplasty surgerySpinal SurgeryThoracic surgeryOutcomesReduction (mg)/RR\
*Estimate (95% CI; p-value; trials)*Test for subgroup differences\
*P-value*Reduction (mg) /RR\
*Estimate (95% CI; p-value; trials)*Test for subgroup differences\
*P-value*Reduction (mg) /RR\
*Estimate (95% CI; p-value; trials)*Test for subgroup differences\
*P-value*Reduction (mg) /RR\
*Estimate (95% CI; p-value; trials)*Test for subgroup differences\
*P-value*Reduction (mg) /RR\
*Estimate (95% CI; p-value; trials)*Test for subgroup differences\
*P-value*Reduction (mg)/RR\
*Estimate (95% CI; p-value; trials)*Test for subgroup differences\
*P-value*Beneficial outcomes 24-h morphine consumption\
*Low risk of bias*12.2 mg\
(9.8, 14.6; 1 trial)-1.6 mg\
(−4.8, 8.0; 2 trials)*P* = 0.21\--4.0 mg\
(−0.8, 8.7; 3 trials)*P* = 0.75\--6.7 mg\
(−2.0, 15.4; 1 trial)- 24-h morphine consumption\
*All trials*7.3 mg\
(95% CI: 4.6, 9.9; *p* \< 0.00001; 10 trials; TSA adj.CI: 3.5, 11.0; 62.4%)*P* = 0.910.5 mg\
(95% CI: 6.7, 14.4; *p* \< 0.00001; 14 trials; TSA adj. CI: 3.0, 18.1; 30.2%)*P* = 0.165.2 mg\
(95% CI: 0.9, 9.5; *p* = 0.02; 6 trials; TSA adj. CI: −4.6, 15.0; 24.3%)*P* = 0.156.1 mg\
(95% CI: 0.2, 12.1; *p* = 0.04; 6 trials; TSA adj.CI: −18.1, 30.3; 5.8%)*P* = 0.4710.6 mg\
(95% CI: 2.1, 19.0; *p* = 0.01; 8 trials; TSA adj.CI: −24.1, 45.2; 6.1%)*P* = 0.526.3 mg\
(95% CI: 2.9, 9.8; *p* = 0.0003; 7 trials; TSA adj.CI: −0.3, 12.3; 28.9%)*P* = 0.25Harmful outcomes Serious adverse events\
*Low risk of bias*Not estimable\-\-\-\--2.98\
(0.36, 24.41; two trials)*P* = 0.49\--1.35\
(0.69, 2.63; two trials)*P* = 0.49 Serious adverse events\
*All trials*Not estimable-0.55\
(95% CI: 0.05, 5.61; p 0.61; 5 trials; TSA adj. CI -; 3.3%)*P* = 0.16Not estimable-2.98\
(95% CI: 0.36, 24.41; *p* = 0.31; 2 trials; TSA adj. CI: -; 2.1%)*P* = 0.3Not estimable-1.06\
(95% CI: 0.57, 1.74; *p* = 0.81; 4 trials; TSA adj.CI: 0.5, 2.1; 55.9%)*P* = 0.72 Table 3Secondary outcomes from trials with low risk of bias and all trialsSurgical procedureCholecystectomyHysterectomyMastectomyOrthopedic arthroplasty surgerySpinal SurgeryThoracic surgeryOutcomesReduction (mm)/RR\
*Estimate (95% CI; p-value; trials)*Test for subgroup differences\
*P-value*Reduction (mm)/RR\
*Estimate (95% CI; p-value; trials)*Test for subgroup differences\
*P-value*Reduction (mm)/RR\
*Estimate (95% CI; p-value; trials)*Test for subgroup differences\
*P-value*Reduction (mm)/RR\
*Estimate (95% CI; p-value; trials)*Test for subgroup differences\
*P-value*Reduction (mm)/RR\
*Estimate (95% CI; p-value; trials)*Test for subgroup differences\
*P-value*Reduction (mm)/RR\
Estimate (95% CI; *p*-value; trials)Test for subgroup differences\
*P*-valueBeneficial outcomes 6-h VAS at rest\
*Low risk of bias*26.0 mm\
(24.8, 27.2; 1 trial)-3.0 mm\
(−12.9, 18.9; 1 trial)\-\-\-\-\-\--5.0 mm\
(−0.7, 10.7; 2 trials)*P* = 0.36 6-h VAS at rest\
*All trials*13.6 mm\
(95% CI: −6.2, 33.4; *p* = 0.18; 3 trials; TSA adj. CI: -; 4.4%)*P* = 0.8716.4 mm\
(95% CI: 11.9, 21.0; *p* \< 0.00001; 16 trials; TSA adj. CI: 11.9, 21.0; 104.3%)*P* = 0.057.8 mm\
(95% CI: 1.9, 13.7; *p* = 0.01; 7 trials; TSA adj. CI: −1.1, 16.7; 51.9%)*P* = 0.15Not estimable-10.2 mm\
(95% CI: 2.3, 18.0; *p* = 0.01; 7 trials; TSA adj. CI: −5.7, 26.0; 29.6%)*P* = 0.596.6 mm\
(95% CI: 0.8, 12.4; *p* = 0.05; 6 trials; TSA adj.CI: −3.0, 12.3; 59.2%)*P* = 0.02 6-h VAS at mobilization\
*Low risk of bias*11.5 mm\
(10.3, 12.7; 1 trial)-13.0 mm\
(−26.0, 52.0; 1 trial)\-\-\-\-\-\--8.9 mm\
(1.6, 16.1; 1 trial)- 6-h VAS at mobilization\
*All trials*11.5 mm\
(95%CI: 10.3, 12.7; *p* \< 0.00001; 1 trial; TSA adj. CI: -)*P* = 0.048.5 mm\
(95%CI: 2.8, 14.2; *p* = 0.004; 6 trials; TSA adj.CI: 0.2, 16.7; 56.1%)*P* = 0.975.2 mm\
(95%CI: −1.6, 12.0; *p* = 0.14; 6 trials; TSA adj.CI: −5.1, 15.7; 44.8%)*P* = 0.07Not estimable-10.0 mm\
(95%CI: 1.1, 19.0; *p* = 0.03; 1 trial; TSA adj. CI: -)*P* = 0.7310.9 mm\
(95%CI: 4.4, 17.4; *p* = 0.001; 4 trials; TSA adj.CI: 0.1, 21.7; 42.8%)*P* = 0.41 24-h VAS at rest\
*Low risk of bias*7.0 mm\
(5.8, 8.2; 1 trial)-9.0 mm\
(−2.8, 20.8; 1 trial)\-\--0.9 mm\
(−6.3, 8.1; 1 trial)\-\--4.2 mm\
(−0.2, 8.5; 2 trials)*P* = 0.06 24-h VAS at rest\
*All trials*3.2 mm\
(95% CI: −1.9, 8.4; *p* = 0.22; 3 trials; TSA adj.CI: −3.3, 9.8; 69.1%)*P* = 0.110.5 mm\
(95% CI: 6.9, 14.2; *p* \< 0.00001; 15 trials; TSA adj.CI: 6.7, 14.4; 136.3%)*P* = 0.022.6 mm\
(95% CI: −3.2, 8.5; *p* = 0.2; 3 trials; TSA adj. CI: −3.2, 8.5; 112.9%)*P* = 0.021.0 mm\
(95% CI: −1.7, 3.7; *p* = 0.45; 3 trials; TSA adj.CI: −3.9, 6.0; 248.0%)*P* = 0.0016.2 mm\
(95% CI: 0.9, 11.6; *p* = 0.02; 6 trials; TSA adj.CI: 0.9, 13.3; 64.1%)*P* = 0.619.7 mm\
(95% CI: 2.4, 17.1; *p* = 0.01; 8 trials; TSA adj.CI: −4.2, 23.7; 33.6%)*P* = 0.51 24-h VAS at mobilization\
*Low risk of bias*16.0 mm\
(15.1, 16.9; 1 trial)-0.5 mm\
(−36.5, 37.5; 1 trial)\-\--0.5 mm\
(−11.4, 12.3; 1 trial)\-\--0.1 mm\
(−8.9, 9.1; 1 trial)- 24-h VAS at mobilization\
*All trials*16.0 mm\
(95% CI: 15.1, 16.9; *p* \< 0.0001; 1 trial; TSA adj. CI: -)*P* \< 0.000017.7 mm\
(95% CI: −8.2, 23.6; *p* = 0.34; 5 trials; TSA adj.CI: −16.3, 25.4; 22.5%)*P* = 0.913.1 mm\
(95% CI: −13.6, 19.8; *p* = 0.72; 3 trials; −65.1, 71.3; 6.5%)*P* = 0.87Increase 6.5 mm (95% CI: 3.0, 9.9;\
*p* = 0.0002; 2 trials; TSA adj.CI: +2.5, +10.5; 150.7%)*P* = 0.0008Not estimable-3.0 mm\
(95% CI: −4.5, 10.4; *p* = 0.43; 6 trials; TSA adj.CI: −11.2, 17.1; 33.1%)*P* = 0.86Harmful outcomes Nausea\
*Low risk of bias*\-\-\-\-\--0.8\
(0.6,1.0; 2 trials)*P* = 0.5\--0.7\
(0.5, 0.9; 1 trial)- Nausea\
*All trials*0.5\
(95% CI: 0.25, 0.99; *p* = 0.05; 1 trial; TSA adj. CI: -)*P* = 0.160.77\
(95% CI: 0.63, 0.95; *p* = 0.01; 11 trials; TSA adj. CI: 0.6, 1.1; 49.4%)*P* = 0.731.38\
(95% CI: 0.85, 2.23; *p* = 0.19; 3 trials; TSA adj. CI: -; 2.69%)*P* = 0.330.83\
(95% CI: 0.66, 1.03; *p* = 0.08; 4 trials; TSA adj. CI: -; 79.7%)*P* = 0.911.07\
(95% CI: 0.68, 1.68; *p* = 0.78; 8 trials; TSA adj. CI: 0.4, 3.2; 22.8%)*P* = 0.290.66\
(95% CI: 0.5, 0.88; *p* = 0.005; 5 trials; TSA adj. CI: 0.4, 1.0; 49.9%)*P* = 0.1 Vomiting\
*Low risk of bias*\-\-\-\-\-\-\-\-\--1.1\
(0.7, 1.6; 1 trial)- Vomiting\
*All trials*0.5\
(95%CI: 0.21, 1.16; *p* = 0.11; 1 trial; TSA adj. CI: -)*P* = 0.280.71\
(95% CI: 0.57, 0.9; *p* = 0.005; 9 trials; TSA adj. CI: 0.5, 1.0; 71.7%)*P* = 0.610.81\
(95% CI: 0.48, 1.37; *p* = 0.44; 5 trials; TSA adj. CI: 0.1, 6.9; 16.5%)*P* = 0.920.64\
(95% CI: 0.26, 1.59; *p* = 0.34; 1 trial; TSA adj. CI: -)*P* = 0.660.61\
(95% CI: 0.33, 1.12; *p* = 0.11; 7 trials; TSA adj. CI: 0.2, 2.3; 18.6%)*P* = 0.511.01\
(95% CI: 0.69, 1.49; *p* = 0.96; 5 trials; TSA adj. CI: 0.2, 4.9; 8.0%)*P* = 0.32 Sedation\
*Low risk of bias*1.8\
(0.8, 3.9; 1 trial)-0.8\
(0.4, 1.6; 1 trial)\-\--0.9\
(0.7, 1.2; 1 trial)\-\--1.2\
(0.7, 2.3; 2 trials)*P* = 0.55 Sedation\
*All trials*3.28\
(95% CI: 1.55, 6.94; *p* = 0.002; 5 trials; TSA adj. CI: -; 3.9%)*P* = 0.0091.08\
(95% CI: 0.81, 1.45; *p* = 0.61; 7 trials; TSA adj. CI: 0.5, 2.2; 23.2%)*P* = 0.061.04\
(95% CI: 0.75, 1.44; *p* = 0.83; 2 trials; TSA adj. CI: -; 4.8%)*P* = 0.060.97\
(95% CI: 0.76, 1.24; *p* = 0.82; 2 trials; TSA adj. CI: 0.7, 1.6; 44.3%)*P* = 0.012.65\
(95% CI: 0.94, 7.52; *p* = 0.07; 7 trials; TSA adj. CI: -; 2.3%)*P* = 0.191.34\
(95% CI: 0.78, 2.32; *p* = 0.29; 5 trials; TSA adj. CI: 0.1, 12.5; 10.8%)*P* = 0.68 Dizziness\
*Low risk of bias*1.0\
(0.7, 1.4; 1 trial)-6.2\
(1.1, 34.0; 1 trial)\-\--0.7\
(0.2, 2.1; 1 trial)\-\--1.0\
(0.8, 1.3; 2 trials)*P* = 0.64 Dizziness\
*All trials*0.7\
(95% CI: 0.52, 0.94; *p* = 0.02; 6 trials; TSA adj. CI: 0.2, 2.6; 27.1%)*P* = 0.011.34\
(95% CI: 0.95, 1.89; *p* = 0.1; 11 trials; TSA adj. CI: 0.3, 5.6; 16.8%)*P* = 0.21.03\
(95% CI: 0.74, 1.43; *p* = 0.88; 5 trials; TSA adj. CI: 0.6, 2.1; 31.4%)*P* = 0.840.72\
(95% CI: 0.32, 1.66; *p* = 0.45; 3 trials; TSA adj. CI: 0.0, 18.1; 5.6%)*P* = 0.441.49\
(95% CI: 0.77, 2.86; *p* = 0.24; 6 trials; TSA adj. CI: 0.6, 3.1; 31.4%)*P* = 0.221.04\
(95% CI: 0.85, 1.26; *p* = 0.7; 4 trials; TSA adj. CI: 0.7, 1.5; 36.4%)*P* = 0.66

Primary outcomes {#Sec13}
----------------

### 24-h morphine consumption {#Sec14}

24-h morphine consumption was reported in 51 trials with 4193 patients. \[[@CR21], [@CR23], [@CR26], [@CR28], [@CR30]--[@CR33], [@CR35]--[@CR44], [@CR46], [@CR48]--[@CR53], [@CR55], [@CR57], [@CR59]--[@CR63], [@CR65]--[@CR70], [@CR72], [@CR73], [@CR80], [@CR82], [@CR84]--[@CR89], [@CR91]--[@CR93]\] Of these 51 trials, 7 were classified as overall low risk of bias \[[@CR39], [@CR43], [@CR46], [@CR59], [@CR72], [@CR73], [@CR85]\].

In cholecystectomy, one trial reported a reduction of 12.2 mg \[9.8, 14.6\] in 24-h morphine consumption in the gabapentin treatment group compared to controls \[[@CR85]\], two trials in hysterectomy found a reduction of 1.6 mg \[−4.8, 8.0\] \[[@CR39], [@CR43]\], and three trials in orthopedic arthroplasty demonstrated a reduction of 4.0 mg \[−0.8, 8.7\] \[[@CR58], [@CR71], [@CR72]\]. Finally, one trial in thoracic surgery reported a reduction of 6.7 mg \[−2.0, 15.4\] \[[@CR46]\]. We found no difference between the surgical procedures when tested for subgroup differences.

(Table [2](#Tab2){ref-type="table"}: The intervention effect estimated from trials with low risk of bias, and from all trials despite risk of bias; Fig. [4](#Fig4){ref-type="fig"}: Forest plot of 24-h morphine consumption from trials with low risk of bias).Fig. 4Forest plot of 24-h morphine consumption. Forest plot of 24-h morphine consumption of trials with overall low risk of bias

(Additional file [1](#MOESM1){ref-type="media"}: Appendix 3 - Forest plot of 24-h morphine consumption from all trials, Additional file [1](#MOESM1){ref-type="media"}: Appendix 4--9 - TSA of estimates from all trials and cholecystectomy, hysterectomy, mastectomy, orthopedic arthroplasty, spinal and thoracic surgery groups).

### Serious adverse events {#Sec15}

Fifteen trials with 1377 patients reported SAEs \[[@CR20], [@CR33], [@CR34], [@CR38], [@CR39], [@CR44], [@CR46], [@CR49], [@CR53], [@CR56], [@CR59], [@CR72], [@CR85], [@CR91], [@CR92]\]. Of the 15 trials, 5 were classified as overall low risk of bias \[[@CR46], [@CR56], [@CR59], [@CR72], [@CR85]\]. The reported SAEs were: Death, urticarial rash, re-operation, prolonged admission, re-admission to hospital, pneumonia, and atrial fibrillation.

One cholecystectomy trial, two orthopedic arthroplasty trials, and two thoracic surgery trials were classified as overall low risk of bias. \[[@CR46], [@CR56], [@CR59], [@CR72], [@CR85]\] In the trials with low risk of bias, the risk of SAE's were 2.98 \[0.36, 24.41\] in the orthopedic arthroplasty subgroup \[[@CR59], [@CR72]\] and 1.35 \[0.69, 2.63\] in the thoracic subgroup \[[@CR46], [@CR56]\]. A comparison of pooled-estimates in test for subgroup differences from trials with low risk of bias indicated no difference between groups, *p* =  0.49.

(Table [2](#Tab2){ref-type="table"}: SAEs estimated from trials with low risk of bias, and from all trials despite risk of bias; Fig. [5](#Fig5){ref-type="fig"}: Forest plot of SAEs from trials with low risk of bias.Fig. 5Forest plot of serious adverse events. Forest plot of Serious Adverse Events of trials with overall low risk of bias

(Additional file [1](#MOESM1){ref-type="media"}: Appendix 10 - Forest plot of SAEs in all trials, Appendix 11 - TSA of SAEs in the thoracic surgery subgroup).

Secondary outcomes {#Sec16}
------------------

### Pain intensity {#Sec17}

In general, only few data were available from trials with low risk of bias, rendering tests for subgroup differences impossible and/or unreliable.

(Table [3](#Tab3){ref-type="table"}: The intervention effect estimated from trials with low risk of bias, and from all trials despite risk of bias).

(Additional file [1](#MOESM1){ref-type="media"}: Appendix 12--15 - Forest plots of VAS 6 h postoperative at rest and mobilization, 24 h postoperative at rest and mobilization, all trials estimates).

### Adverse events {#Sec18}

No subgroup differences were demonstrated in any adverse event in trials with low risk of bias.

(Table [3](#Tab3){ref-type="table"}: Adverse events estimated from trials with low risk of bias, and from all trials despite risk of bias).

(Additional file [1](#MOESM1){ref-type="media"}: Appendix 16--19 - Forest plots of nausea, vomiting, sedation and dizziness, all trials).

Discussion {#Sec19}
==========

It has been argued that postoperative pain treatment should be "procedure-specific", since different analgesics may have specific effects dependent on the surgical procedure \[[@CR4], [@CR5]\]. In the present, preplanned subgroup analyses, we aimed to compare the effects of perioperative gabapentin on postoperative opioid consumption, pain intensity, and adverse- and serious adverse events in six different surgical procedures. Our primary outcomes were 24-h morphine consumption and the risk of SAEs.

Our results are limited by the fact that overall, only eight trials were classified as overall low risk of bias, limiting our ability to test for subgroup differences, and to pool estimates in meta-analyses of these eight trials. When interpreting the results from the all trials analyses, it should be noted that about two-thirds of these trials had overall high risk of bias, which is a severe limitation to any conclusion on the outcomes.

In trials with low risk of bias, 24-h morphine consumption varied, and only the cholecystectomy subgroup indicated a difference between groups. With only one trial in this subgroup, the result has not been reproduced, and is difficult to interpret.

For the analysis of all trials, the difference in 24-h morphine consumption between surgical procedures was not statistically significant, when tested for subgroup differences. A reduction in 24-h morphine consumption was demonstrated for all surgical procedures compared with controls. However, the TSA did not reach required information size in any subgroup. Consequently, the effects observed in the individual procedures may be due to both random and systematic error, as indicated in the main systematic review \[[@CR12]\].

SAEs were primarily reported in the thoracic surgery trials but overall, since SAEs were very poorly reported and data was sparse, it is not possible to conclude on this outcome.

For pain intensity outcomes, very few data were available from trials with low risk of bias. In the analyses of data from all trials, the results were divergent across surgical subgroups, and it is difficult to interpret the direction and authenticity in the test for subgroup differences.

No subgroup difference was demonstrated for any adverse event in trials with low risk of bias, and results from data including all trials were divergent across surgical subgroups, with no consistent differences in adverse events between surgical procedures. This indicates a similar adverse event profile of gabapentin for postoperative pain management irrespective of surgical procedure. Much like the previous outcomes, there is far too few data to firmly conclude based on these results. Poor reporting and high risk of bias limits any interpretation.

Strengths and limitations of the subgroup analyses {#Sec20}
--------------------------------------------------

These subgroup analyses have some strength. The analyses were planned in a PROSPERO published protocol, and were derived from a PRISMA compliant systematic review adhering to Cochrane standards in methodology and bias assessment. The trials have been critically assessed using the Cochrane bias assessment tools, and conclusions are based on trials with low risk of bias, which is unlike most of the previous systematic reviews. The TSA has been added to adjust for sparse data and repetitive resting, which is a risk when the vast majority of included trials are small, that is \<50 patients in each group \[[@CR95]--[@CR98]\].

The limitations of this analysis mirror those of the included trials, and the limitations of the general methodology in subgroup analyses. Subgroup comparisons are to be perceived as observational because we compare pre-existing non-randomized groups, and must be interpreted as such \[[@CR14]\].

The critical assessment of the trial methodology shows a very small number of trials with overall low risk of bias. Eighty-nine percent of the included trials have unclear or high risk of bias in one of the bias domains or more, risking an overestimation of beneficial -, and underestimation of harmful outcomes.

Despite the larger number of included trials in each subgroup compared with previous published systematic reviews, there is still a risk of spurious results due to lack of sufficient data. The lack of statistically significant *p*-values in the present subgroup analyses may be due to a small effect size, or poor power to detect a large effect.

According to Oxman and Guyatt \[[@CR99]\], Xin Sun et al \[[@CR100]\] and their criteria to evaluate the credibility of subgroup analyses, we have to consider further limitations such as: If the subgroup can be considered independent; no a-priori direction of the subgroup effect has been published; the subgroup effects found in our analyses does not seem to consequently manifest in closely related outcomes.

Relation to the previously published systematic reviews {#Sec21}
-------------------------------------------------------

A number of systematic reviews investigating individual surgical procedures, or with a procedure specific approach, have been published \[[@CR95]--[@CR98], [@CR101]--[@CR103]\]. Overall, there are some general methodological differences that separates the present work from previously published systematic reviews, such as: The emphasis on trials with low risk of bias, subgroup analyses with test for subgroup differences, and the use of trial sequential analyses. The emphasis on trials with low risk of bias prevents any direct comparison with estimates from other systematic reviews. Several reviews have evaluated bias in the included trials, and report different overall bias evaluations and number of trials with overall low risk of bias, compared to the present review \[[@CR97], [@CR98], [@CR104]\]. This may be explained by the fact that that we contacted every author whenever a bias domain was deemed unclear risk of bias, to give them a chance to describe their methods in greater detail. To our knowledge, this was not done in the previously published systematic reviews.

In a recent review, the effect of trials with high risk of bias were tested using sensitivity analyses, and no impact was demonstrated on the outcomes \[[@CR104]\]. This is in contrast to the present analyses, and to the findings of our recently published systematic review \[[@CR12], [@CR104]\]. The different approach to author contact, and a different statistical approach, may explain some of the differences in the findings. Further, the systematic review by Doleman et al. \[[@CR104]\] reports that the type of surgery was not independently associated with the effect of gabapentin, which may provide some confirmation of the results from the present analyses. However, the results are obtained with different statistical approaches and the number and types of surgeries are not stated in the findings from Doleman et al. Consequently, the confirmation must be interpreted with caution \[[@CR104]\]. In another review, Mathiesen et al. demonstrated a greater beneficial effect (reduction in 24-h opioid consumption) in their hysterectomy and spinal surgery groups \[[@CR95]\], which seems similar to the results from the all trials estimates in Table [2](#Tab2){ref-type="table"} in the present review. Mathiesen et al., however, did not test for subgroup differences \[[@CR95]\], and we found no differences between subgroups in the all trials estimates of the present review.

Most previous systematic reviews report favorable results for gabapentin treatment, similar to the findings from the all trials estimates in the subgroup analyses of the present review. In comparison with the systematic reviews of gabapentin for hysterectomy, cholecystectomy and thoracic surgeries \[[@CR95], [@CR96], [@CR101]\], more trials have been included in our subgroups. Due to different inclusion criteria and subgroup analyses in the different published systematic reviews, it is not possible to conduct a full comparison of estimates.

However, none of the systematic reviews above have investigated the risk of SAEs, limiting the ability to weigh the benefit and harm of gabapentin in perioperative pain management \[[@CR95]--[@CR98], [@CR101]\].

Impact of the analyses {#Sec22}
----------------------

We observed no systematic differences in postoperative opioid consumption, pain intensity, or adverse- or serious adverse events between six different surgical procedures treated with peri-operative gabapentin.

SAEs were very poorly reported, and only half the subgroups reported this outcome. More than 80% of the SAEs were reported in the thoracic surgery trials, making it impossible to rely on the risk and subgroup differences between the surgical procedures. In the original review, excess SAEs were reported in the gabapentin versus control groups, and approximately twice as many SAEs were found in trials with low risk of bias, compared with all trials \[[@CR13]\]. Most trials have a short follow-up period and only report on SAEs and adverse effects for a short period postoperatively, which seems insufficient for a full evaluation. The inconsequent and diverse reporting of SAEs and adverse events complicates any reliable evaluation of these outcomes.

Conclusion {#Sec23}
==========

Both beneficial and harmful effects in the present subgroup analyses are influenced by bias and insufficient data, limiting any conclusion. The very poorly reported incidence of SAEs limits any conclusion based on this outcome. Because of these limitations, we could not properly test for any major differences in beneficial or adverse outcomes between various surgical subgroups with gabapentin for postoperative pain. Consequently, our analyses cannot confirm or reject the concept of a procedure specific effect of gabapentin on postoperative pain.

Additional files
================

 {#Sec24}

Additional file 1:**Appendix 1.** Search strategies. **Appendix 2.** Opioid conversion table. **Appendix 3.** Forest plot of 24-h morphine consumption from all trials estimates. **Appendix 4.** TSA of 24-h morphine consumption in the cholecystectomy subgroup, all trials. **Appendix 5.** TSA of 24-h morphine consumption in the hysterectomy subgroup, all trials. **Appendix 6.** TSA of 24-h morphine consumption in the mastectomy subgroup, all trials. **Appendix 7.** TSA of 24-h morphine consumption in the orthopedic arthroplasty subgroup, all trials. **Appendix 8.** TSA of 24-h morphine consumption in the spinal subgroup, all trials. **Appendix 9.** TSA of 24-h morphine consumption in the thoracic surgery subgroup, all trials. **Appendix 10.** Forest plot of SAEs, all trials. **Appendix 11.** TSA of SAEs in the thoracic surgery subgroup, all trials. **Appendix 12.** Forest plot of VAS 6 h at rest, all trials. **Appendix 13.** Forest plot of VAS 6 h at mobilization, all trials. **Appendix 14.** Forest plot of VAS 24 h at rest, all trials. **Appendix 15.** Forest plot of VAS 24 h at mobilization, all trials. **Appendix 16.** Forest plot nausea, all trials. **Appendix 17.** Forest plot vomiting, all trials. **Appendix 18.** Forest plot sedation, all trials. **Appendix 19.** Forest plot dizziness, all trials. (PDF 736 kb)

CI

:   Confidence interval

D

:   Day

GA

:   General anesthesia

ICH-GCP

:   International committee of harmonization -- good clinical practice

ICMJE

:   International committee of medical journal editors

NSAID

:   None-steroid anti-inflammatory drugs

PRISMA

:   Preferred reporting items for systematic reviews and meta-analyses

RCT

:   Randomized, clinical trial

SAE

:   Serious adverse events

TSA

:   Trial sequential analysis
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